Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin.
During continuous ambulatory peritoneal dialysis (CAPD) the peritoneal immune cells, mainly macrophages, are highly compromised by multiple factors including oxidative stress, resulting in a loss of functional activity. One reason for the increase of inflammatory reactions could be an imbalance in the thiol-disulfide status. Here, the possible protective effects of the antioxidant flavonoid complex silymarin and its major component silibinin on the cellular thiol status were investigated. Peritoneal macrophages from dialysis fluid of 30 CAPD patients were treated with silymarin or silibinin up to 35 days. A time-dependent increase of intracellular thiols was observed with a nearly linear increment up to 2.5-fold after 96 hours, reaching a maximum of 3.5-fold after 20 days of culture. Surface-located thiols were also elevated. The stabilization of the cellular thiol status was followed by an improvement of phagocytosis and the degree of maturation as well as significant changes in the synthesis of IL-6 and IL-1ra. Furthermore, the treatment of peritoneal macrophages with flavonoids in combination with cysteine donors resulted in a shortened and more efficient time course of thiol normalization as well as in a further increased phagocytosis. In addition, GSH-depletion in thiol-deficient media simulating CAPD procedures led to intracellular thiol deficiency similar to the in vivo situation. It is concluded that treatment with milk thistle extracts silymarin and silibinin alone or, more effectively in combination with cysteine donors, provide a benefit for peritoneal macrophages of CAPD-patients due to a normalization and activation of the cellular thiol status followed by a restoration of specific functional capabilities.
Täger
M
M
Institute of Immunology, Otto-von-Guericke University, Leipziger Str. 44 D-39120 Magdeburg, Germany. michael.tager@medizin.uni-magdeburg.de
Dietzmann
J
J
Thiel
U
U
Hinrich Neumann
K
K
Ansorge
S
S
D000111:Acetylcysteine / Q000494:pharmacology; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis; D002478:Cells, Cultured / Q000187:drug effects; D004396:Coloring Agents; D003545:Cysteine / Q000502:physiology; D005260:Female; D005434:Flow Cytometry; D005452:Fluoresceins / Q000032:analysis; D005786:Gene Expression Regulation / Q000187:drug effects; D005978:Glutathione / Q000502:physiology; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D015850:Interleukin-6 / Q000096:biosynthesis / Q000235:genetics; D017737:Macrophages, Peritoneal / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D010587:Phagocytosis / Q000187:drug effects; D012795:Sialoglycoproteins / Q000096:biosynthesis / Q000235:genetics; D012838:Silymarin / Q000494:pharmacology*; D013438:Sulfhydryl Compounds / Q000378:metabolism*
D015703:Antigens, CD; D004396:Coloring Agents; D005452:Fluoresceins; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D015850:Interleukin-6; D012795:Sialoglycoproteins; D012838:Silymarin; D013438:Sulfhydryl Compounds; C069306:5-chloromethylfluorescein; D005978:Glutathione; D003545:Cysteine; D000111:Acetylcysteine